Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]Raclopride PET study

Movement Disorders

Volumn 14, Issue 6, 1999, Pages 1025-1030

  Dentresangle, Christine ^a,b   Veyre, Laurent ^a   Le Bars, Didier ^a   Pierre, Christian ^a   Lavenne, Frank ^a   Pollak, Pierre ^c   Guerin, Jeanine ^d   Froment, Jean Claude ^e   Brousolle, Emmanuel ^b,f  

^a CERMEP IMAGERIE DU VIVANT   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIV GRENOBLE ALPES   (France)

^d Lab Neuropsychol Cogn F   (France)

^e NONE   (France)

^f Service de Neurologie D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN RECEPTOR; BROMOCRIPTINE; CARBON 11; DECARBOXYLASE INHIBITOR; DOPA; DOPAMINE 2 RECEPTOR; FLUORINE 18; LEVODOPA; PIRIBEDIL; RACLOPRIDE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; ANTIPARKINSON AGENTS; BRAIN MAPPING; CARBIDOPA; CARBON RADIOISOTOPES; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DRUG COMBINATIONS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RACLOPRIDE; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032703626     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199911)14:6<1025::AID-MDS1020>3.0.CO;2-P     Document Type: Article

References (31)

1. Bernheimer H, Birkmayer W, Hornyckiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49: 853-860.
3. 18F]dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
4. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
5. Rutgers AWF, Lakke JPWF, Paans AMJ, Vaalburg W, Korf J. Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography. J Neurol Sci 1987;80:237-248.
6. Rinne UK, Laihinen A, Rinne OJ, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
7. 11C]Raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
8. 11C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325-1329.
9. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-1190.
10. 11C]Raclopride. Mov Disord 1997;12:33-38.
11. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49: 717-723.
12. Uitti RJ, Vingerhoets FJG, Hayward M, Cooper S, Snow BJ. Positron emission tomography (PET) measurements of striatal D2 receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with Sinemet or Sinemet CR. Parkinsonism & Related Disorders 1997;3:43-46.
13. 3H]-Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984;99: 167-175.
14. Leenders KL, Herold S, Brooks DJ. Pre-synaptic and post-synaptic dopaminergic system in human brain. Lancet 1984;2:110-111.
15. Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtelotte WW. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol 1986;19:487-492.
16. Cortés R, Camps M, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 1989;483:30-38.
17. 123I]IBZM binding compared with long-term clinical follow-up in patients with de novo parkinsonism. Mov Disord 1998;13:16-19.
18. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187-2195.
19. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. Brain 1993;116:853-867.
20. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
21. Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterisation. Brain Res 1980;195:123-137.
22. Zhang WQ, Tilson HA, Nanry KP, Hudson PM, Hong JS, Stachowiak MK. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 1988;461: 335-342.
23. Robinson TE, Whishaw IQ. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OH-DA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 1988;450:209-224.
24. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral sensitivity. Science 1977;197:596-598.
25. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DH. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D2-receptor density. Brain Res 1985;382:360-364.
26. Fahn S, Elton RL, and the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Development in Parkinson's Disease. Florham Park, NJ: Macmillan, 1987:293-304.
27. 18F]Fluoro-L-dopa via two chiral auxiliaries. Journal of Applied Radiations and Isotopes 1993;44:737-744.
28. 11C)-labelled raclopride-specific dopamine D2 receptors ligands. Journal of Labelled Compounds Radiopharmaceuticals 1987;24:931-939.
29. Chritin M, Blanchard V, Raisman-Vozari R, et al. Dopamine uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration. Eur J Neurosci 1996;8:2511-2520.
30. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
31. 11C]raclopride displacement and PET. Neurology 1996;46:1431-1436.